Kyowa Kirin
The Director of Technology Development Research leads a group focused on allogeneic immune cell therapy and cell and gene therapy technology development, overseeing scientific strategy, project execution, and cross‑functional collaboration. The role provides senior technical leadership in iPSC biology, genome editing, and related platform technologies while managing staff, resources, and external partnerships.
Kyowa Kirin is a Japanese biopharmaceutical company that develops innovative specialty medicines, with a particular focus on antibody‑based therapies for cancer, kidney disease, and immune‑mediated disorders. The company pursues technology‑driven drug discovery across biologics and small molecules and maintains a broad global network of research, development, and commercial operations. Kyowa Kirin advances a pipeline through internal R&D and strategic partnerships (including biologics and CDMO collaborations) to bring life‑changing treatments to patients. It emphasizes patient‑centred value, scientific expertise, and sustainability in its mission to raise health and well‑being worldwide.
Kyowa Kirin Integrates North America Businesses in Support of Company's 2030 Vision and Rapid Growth Trajectory
Mar 31, 2021
La Jolla Institute renews longtime collaboration with Kyowa Kirin, Inc.
Jan 18, 2022
Kyowa Kirin Completes New North American Headquarters in Princeton
Jul 11, 2023
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Kyowa Kirin.
5% above the average for this role
How Kyowa Kirin is Giving Employees a Voice in the Company’s Future
Dec 7, 2023